-
Posted by
Two Blokes Tue at 9:15 AM -
Filed in
Stock
-
0 views
Shares of Iovance Biotherapeutics (IOVA -5.91%) are down about 75% from a high-water mark they set last December. Up and down Wall Street, investment bank analysts tasked with following the commercial-stage cancer drug developer are arguing about whether it's fallen too far or not far enough.
